Business intelligence and the telecommunications industry : can business intelligence lead to higher profits?

Organizations are finding it increasingly difficult to increase profits as competition in the marketplace continually pressurizes margins. Organizations will have to do more to enjoy sustainable profits in the future and information technology could arguably be the key to assisting management with the task of increasing profits on a sustainable basis. Business intelligence (BI) could be the competitive advantage for organizations to increase profitability. South Africa is faced with an unemployment rate of over 40% and it is not desirable that costs are contained by reducing staff. It is clear that innovative ideas should be looked at to ensure that organizations continue to make profits. Information management programmes offer the necessary tools to ensure that efficient and strategic decisions are made

Simulation-assisted control in building energy management systems

Technological advances in real-time data collection, data transfer and ever-increasing computational power are bringing simulation-assisted control and on-line fault detection and diagnosis (FDD) closer to reality than was imagined when building energy management systems (BEMSs) were introduced in the 1970s. This paper describes the development and testing of a prototype simulation-assisted controller, in which a detailed simulation program is embedded in real-time control decision making. Results from an experiment in a full-scale environmental test facility demonstrate the feasibility of predictive control using a physically-based thermal simulation program

Utilization of health care services by patients with chronic obstructive pulmonary disease

AbstractIn order to identify healthcare resource use patterns associated with chronic obstructive pulmonary disease (COPD), resource utilization (RU) data collection was integrated into a randomized, double-blind placebo-controlled study of Viozan™ (sibenadet HCI). This study enrolled patients with symptomatic, smoking-related COPD, randomized to receive sibenadet or placebo for a 52-week treatment period. A questionnaire establishing typical pre-trial, COPD, randomized to RU was completed by each patient. Subsequent data were collected by means of an Interactive Voice Response System (IVRS) at 30-day intervals (14 time points) during the study and in the follow-up period. The IVRS system facilitated data collection and minimized inconvient to the patients. Subsequent data were collected by means of an Interactive Voice Response System health services during the year-long study was high.No overall trend for lower RU was associated with sibenadet therapy, which correlates with the lack of sustained clinical effect seen in studies conducted concurrently. These data do, however, provide valuable information on RU associated with COPD and insights into adjustments associated with changes in disease course. Physicians were seen to be the most common source of care for patients with COPD and more of the patients with severe COPD (stage III) than mild (stage I) were seen to utilize the most expensive resources (e.g. inpatient hospital care). For those patients who experienced an exacerbation during the trial (irrespective of treatment group), resource use was increased during the periods when an exacerbation was reported when compared with the periods before or after an exacerbation. The proportion of cases attending the physician doubled and with a trip to the Emergency Room (ER) increased approximately ninefold during the reporting period in which the exacerbation occurred compared with the previous month.This study has shown that use of an IVRS, even in elderly patients, is an effective means of gathering RU data over long periods. The study findings suggest that the advent of effective therapeutic interventions, particularly any with the ability to minimize exacerbations and limit disease progression, could impact on the health care services used and potentially reduce associated costs

Nonthermal fragmentation of C60

A theoretical study of the subpicosecond fragmentation of C60 clusters in response to ultrafast laser pulses is presented. We simulate the laser excitation and the consequent nonequilibrium relaxation dynamics of the electronic and nuclear degrees of freedom. The first stages of the nonequilibrium dynamics are dominated by a coherent breathing mode followed by the cold ejection of single C atoms, in contrast to the dimer emission which characterizes the thermal relaxation. We also determine the nonequilibrium damage thresholds as a function of the pulse duration.Comment: 5 pages, 4 figures, submitted to Chem. Phys. Let

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single‐agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high‐risk features. Here we report the final analysis from RESONATE with median follow‐up on study of 65.3 months (range, 0.3‐71.6) in the ibrutinib arm. Median progression‐free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113‐0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418‐0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all‐grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long‐term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high‐risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707)

Male and Female Visions of Mediation

Also PCMA Working Paper #2.http://deepblue.lib.umich.edu/bitstream/2027.42/51102/1/334.pd